Table 3.

Endpoint Comparisons for Subcutaneous Placebo vs Subcutaneous Testosterone (Means and 95% Confidence Intervals)

Endpoint	Placebo (N=26)	Testosterone (N=25)	p-value
Change in BPI-AIA Average Pain Score from Baseline to Month 1	−0.8 (−1.6,−0.1)	−2.0 (−2.8,−1.2)	0.04
Percent of Baseline Hot Flash Frequency at Week 8	59.9% (44%,76%)	35.8% (20%,52%)	0.03
Percent of Baseline Hot Flash Scores at Week 8	48.1% (35%,61%)	28.1% (15%,41%)	0.03
Maximum SED Nausea at Month 3	3.0 (1.8,4.1)	1.1 (0.5,1.7)	0.02
Maximum SED Fatigue at Month 3	7.0 (5.9,8.0)	5.3 (4.2,6.5)	0.04
Maximum SED Mood Swings at Month 3	5.4 (4.2,6.7)	3.5 (2.3,4.7)	0.03
Maximum SED Hand or Feet Swelling at Month 3	4.2 (2.9,5.5)	1.7 (0.8,2.6)	0.01
MENQOL Incidence of Stress Urinary Incontinence at Month 3	42% (22%,63%)	10% (1%,32%)	0.04
MENQOL Incidence of Changes in Appearance, Texture or Tone of Skin at Month 3	46% (26%,67%)	10% (1%,29%)	0.01

BPI-AIA = Modified Brief Pain Inventory for Aromatase Inhibitor Arthralgia

SED = Symptom Experience Diary

MENQOL = Menopause Specific Quality of Life Questionnaire